RU | EN

Press Releases

Press release, 04.09.2020

RDIF and the Gamaleya National Research Center of Epidemiology and Microbiology announce the publication in leading medical journal The Lancet of the results of clinical trials of Phase I-II of the Russian vaccine Sputnik V demonstrating its safety and efficacy

RDIF in the Media

Washington Examiner, 04.09.2020

Russian COVID-19 vaccine shows promise

CNN, 04.09.2020

Russia's Covid-19 vaccine generated an immune response, study says

CNBС, 04.09.2020

Russia's potential coronavirus vaccine shows 'no serious adverse' effects and creates antibody response: The Lancet study

Bloomberg, 04.09.2020

Russia’s Covid Vaccine Shows Potential in Peer Review, Lancet Reports

Reuters, 04.09.2020

Results of Russia's COVID-19 vaccine produced antibody response: The Lancet

Sputnik, 04.09.2020

The Lancet Publishes Results of Russian COVID-19 Vaccine Clinical Trials

Video

Interview of RDIF CEO Kirill Dmitriev to CNBC India

Interview of RDIF CEO Kirill Dmitriev to CNBC India

CNBC India, 04.09.2020

Interview of RDIF CEO Kirill Dmitriev to CNBC Arabia

Interview of RDIF CEO Kirill Dmitriev to CNBC Arabia

CNBC Arabia, 04.09.2020

Interview of RDIF CEO Kirill Dmitriev to NDTV

Interview of RDIF CEO Kirill Dmitriev to NDTV

NDTV, 04.09.2020

UK, U.S. are ‘following Russia’s footsteps’ as they consider approving Sputnik V vaccine, RDIF CEO says

UK, U.S. are ‘following Russia’s footsteps’ as they consider approving Sputnik V vaccine, RDIF CEO says

CNBC Europe, 04.09.2020

Subscribe to news Media Enquiries

Jan, 2020

Feb, 2020

Mar, 2020

Apr, 2020

May, 2020

Jun, 2020

Jul, 2020

Aug, 2020

Sep, 2020

Okt, 2020

Nov, 2020

Dec, 2020